What is Sarepta Therapeutics, Inc.'s D&A?

Sarepta Therapeutics, Inc. (SRPT) reported D&A of $10.59M in Q1 2026.

How has Sarepta Therapeutics, Inc.'s D&A changed year-over-year?

Sarepta Therapeutics, Inc.'s D&A increased by 6.2% year-over-year, from $9.98M to $10.59M.

What is the long-term trend for Sarepta Therapeutics, Inc.'s D&A?

Over 4 years (2021 to 2025), Sarepta Therapeutics, Inc.'s D&A has grown at a 4.0% compound annual growth rate (CAGR), from $38.02M to $44.52M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Sarepta Therapeutics, Inc. SRPT D&A

D&A at other companies

PfizerPFE

$1.61B-0.3%

Regeneron PharmaceuticalsREGN

$123.2M-2.9%

BioMarin PharmaceuticalsBMRN

$16.41M-25.6%

PTC TherapeuticsPTCT

$15.41M+113%

InsmedINSM

$2.93M+55.8%

Capricor TherapeuticsCAPR

$534.67K+31.9%

Segments

By segment

See full

All Other Segments$10.59M+6.2%

Other financials

Income statement

See full

Revenue$730.8M-1.9%

Operating income-$300.4M-961%

Net income$331.0M+174%

EPS (diluted)-$4.60-1,343%

Balance sheet

See full

Cash & equivalents$464.5M+92.8%

Total debt$198.5M-3.4%

Total equity$1.5B+31.7%

Total assets$3.2B-8.3%

Cash flow

See full

Operating cash flow-$202.7M+65.3%

CapEx$2.1M-95.2%

Free cash flow-$204.8M+67.3%

Valuation

See full

Market cap$1.76B-63.1%

Profitability

See full

Operating margin-50.8%-1.6pp

Net margin4.6%+2.4pp

FCF margin-28.7%-9.2pp

Returns & leverage

See full

Return on equity-23.6%-28.5pp

Debt / equity0.1×0.0×

Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s D&A?: Sarepta Therapeutics, Inc. (SRPT) reported D&A of $10.59M in Q1 2026.
How has Sarepta Therapeutics, Inc.'s D&A changed year-over-year?: Sarepta Therapeutics, Inc.'s D&A increased by 6.2% year-over-year, from $9.98M to $10.59M.
What is the long-term trend for Sarepta Therapeutics, Inc.'s D&A?: Over 4 years (2021 to 2025), Sarepta Therapeutics, Inc.'s D&A has grown at a 4.0% compound annual growth rate (CAGR), from $38.02M to $44.52M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.